Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
TAMPA, Fla., October 24, 2022--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including COVID-19, announces its participation in the 2022 BioFlorida Annual Conference, being held November 2-4 in Miami.
TAMPA, Fla., September 30, 2022--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including coronaviruses, today issued the following letter to shareholders from its President and Chief Executive Officer, Kim Murphy.
TAMPA, Fla., August 24, 2022--Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate
TAMPA, Fla., June 23, 2022--Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer
TAMPA, Fla., June 14, 2022--Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports
We've seen this movie before only to watch dip-buyers get fleeced — but money managers are now warming to the idea of a material bounce in stocks.
TAMPA, Fla., April 18, 2022--Oragenics to Participate at the World Vaccine Congress Washington 2022
TAMPA, Fla., April 06, 2022--Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses
TAMPA, Fla., March 25, 2022--Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
TAMPA, Fla., March 22, 2022--Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1